Drug Delivery and Therapeutics at the Australian Centre for Nanomedicine (ACN) brings together expertise in nanotechnology, medicine, chemistry, and engineering to develop smarter ways to treat disease. The focus is on designing advanced delivery systems that can transport therapeutic agents such as drugs, RNA, DNA, and gene-based therapies precisely to where they are needed in the body.
A central challenge in modern medicine is ensuring that treatments reach the right cells safely and effectively. Many therapies fail because they are rapidly broken down, cannot cross biological barriers, or cause harmful side effects in healthy tissues. ACN researchers are addressing these challenges by developing nanoparticles and nanostructured systems that protect therapeutic cargo and deliver it directly to diseased cells. This targeted approach has the potential to improve treatment effectiveness while reducing toxicity.
Research within this theme spans the design, synthesis, and testing of a wide range of delivery platforms, including lipid-based nanoparticles, polymeric carriers, and hybrid nanomaterials. These systems are engineered to navigate the body, recognise specific cell types, and release their payload in a controlled manner. Particular emphasis is placed on enabling emerging therapies such as RNA and DNA delivery, including gene therapies and gene-editing approaches, which hold immense promise but require highly efficient and safe delivery technologies.
The work at ACN addresses diverse disease areas, including cancer, neurological disorders, and cardiovascular disease. For cancer, targeted nanomedicines are being developed to deliver therapies directly to tumours, improving outcomes while minimising damage to healthy tissues. In neurological diseases, researchers are tackling the challenge of crossing the blood-brain barrier to deliver treatments to the brain. In cardiovascular disease, new delivery systems are being explored to repair tissue and restore function.
Strong collaborations with clinicians ensure that research is driven by real clinical needs and patient outcomes. Partnerships with industry also play a key role in advancing promising technologies towards clinical translation and real-world impact.
Through these interdisciplinary efforts, ACN is advancing the next generation of therapeutic platforms enabling more precise, effective, and personalised treatments that have the potential to transform healthcare and improve lives.
